Lexeo Therapeutics (LXEO) EBT (2022 - 2026)
Lexeo Therapeutics (LXEO) posted EBT of -$20.2 million for Q1 2026, up 12.11% sequentially from -$23.0 million in Q4 2025, and up 38.16% YoY from -$14.6 million in Q1 2025.
Lexeo Therapeutics (LXEO) EBT (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported EBT for 5 years, with the latest figure at -$20.2 million in Q1 2026.
- Quarterly EBT rose 38.16% year-over-year to -$20.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$89.6 million (up 18.06% YoY) and the FY2025 annual result came in at -$222.1 million, down 125.83% from the prior year.
- EBT advanced to -$20.2 million in Q1 2026 per LXEO's latest filing, from -$23.0 million in the prior quarter.
- Over five years, EBT peaked at -$13.4 million in Q2 2023 and troughed at -$32.7 million in Q1 2025.
- A 5-year average of -$21.2 million and a median of -$20.3 million in 2025 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2026: EBT sank 82.73% in 2024, then soared 38.16% in 2026.
- Over 5 years, EBT stood at -$14.6 million in 2022, then rose by 2.68% to -$14.2 million in 2023, then sank by 82.73% to -$25.9 million in 2024, then increased by 11.36% to -$23.0 million in 2025, then climbed by 12.11% to -$20.2 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$20.2 million, -$23.0 million, and -$20.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | -25.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.87 Mn |
| Mar 31, 2026 | -20.20 Mn |
| Dec 31, 2025 | -22.98 Mn |
| Sep 30, 2025 | -20.28 Mn |
| Jun 30, 2025 | -26.10 Mn |
| Mar 31, 2025 | -32.66 Mn |
| Dec 31, 2024 | -25.92 Mn |
| Sep 30, 2024 | -29.49 Mn |
| Jun 30, 2024 | -21.24 Mn |
| Mar 31, 2024 | -21.68 Mn |
| Dec 31, 2023 | -14.19 Mn |
| Sep 30, 2023 | -20.11 Mn |
| Jun 30, 2023 | -13.44 Mn |
| Mar 31, 2023 | -18.66 Mn |
| Dec 31, 2022 | -14.58 Mn |
| Sep 30, 2022 | -17.06 Mn |